Maze Therapeutics (NASDAQ:MAZE) Upgraded at Mizuho

Maze Therapeutics (NASDAQ:MAZE) was upgraded by research analysts at Mizuho to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

MAZE has been the subject of several other research reports. BTIG Research restated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Monday. Guggenheim upped their price objective on Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Raymond James Financial began coverage on Maze Therapeutics in a report on Thursday, November 13th. They set an “outperform” rating and a $48.00 price objective for the company. HC Wainwright restated a “buy” rating on shares of Maze Therapeutics in a research note on Wednesday, January 28th. Finally, Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $54.63.

Maze Therapeutics Stock Performance

Shares of MAZE stock opened at $51.83 on Wednesday. The firm has a market cap of $2.49 billion, a price-to-earnings ratio of -2.48 and a beta of 4.47. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $52.57. The firm’s 50-day simple moving average is $44.61 and its two-hundred day simple moving average is $35.34.

Insider Activity

In related news, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction that occurred on Thursday, January 29th. The shares were sold at an average price of $44.27, for a total transaction of $332,025.00. Following the sale, the insider directly owned 10,503 shares in the company, valued at approximately $464,967.81. This represents a 41.66% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CMO Harold Bernstein sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $50.45, for a total transaction of $1,513,500.00. The SEC filing for this sale provides additional information. Insiders have sold a total of 230,000 shares of company stock valued at $9,768,292 over the last quarter.

Hedge Funds Weigh In On Maze Therapeutics

Large investors have recently made changes to their positions in the stock. Royal Bank of Canada grew its position in shares of Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. California State Teachers Retirement System lifted its holdings in Maze Therapeutics by 138.0% during the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after purchasing an additional 766 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its stake in Maze Therapeutics by 18.5% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock worth $247,000 after purchasing an additional 931 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in Maze Therapeutics in the 4th quarter worth about $39,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.